As of November 6, 2026, BeOne Medicines Ltd. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 11, 2026 (Form 8-K, June 11, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like BeOne Medicines Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
BeOne Medicines Ltd. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-11. Every row below is cited to the filing it comes from, and this page adds each new change as BeOne Medicines Ltd. files it.
Also on the record for BeOne Medicines Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 16, 2026 | Stake report, Schedule 13D/A, by Baker Bros. Advisors LP | 7.8% of the class | 5%+ stakes | Source |
| June 15, 2026 | Stake report, Schedule 13D/A, by Baker Bros. Advisors LP | 8% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Capital International Investors | 4.2% of the class | 5%+ stakes | Source |
| April 16, 2026 | Stake report, Schedule 13D/A, by Baker Bros. Advisors LP | 8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs BeOne Medicines Ltd. now and the warning signs.
Free to see. No signup.
Keep reading
More on BeOne Medicines Ltd. and the records around it.
BeOne Medicines Ltd. elsewhere on the record
- 5%+ stake filings Sep 2026
- Who owns it
Companies that share a holder
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), Cerus Corporation (Aug 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
Watch BeOne Medicines Ltd.
Get an email when BeOne Medicines Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BeOne Medicines Ltd.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BeOne Medicines Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BeOne Medicines Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-11 | Reported | not named in the filing | 8-K, 2026-06-11 |
New leaders reset buying decisions — get the Full Report on BeOne Medicines Ltd.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at BeOne Medicines Ltd., with the record behind each one.
Find candidates like senior executive at BeOne Medicines Ltd.Every change, in the filing's words
Reported
Accordingly, their terms as directors, including as members of all committees of the Company's board of directors (the "Board of Directors") on which they served, terminated at the conclusion of the Annual Meeting.
- (b) As previously disclosed in the definitive proxy statement for the 2026 Annual General Meeting of Shareholders (the "Annual Meeting") of BeOne Medicines Ltd. (the "Company") filed with the U.S. Securities and Exchange Commission on April 28, 2026 (the "Proxy Statement"), Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting.
- The decision by each such director not to stand for re-election was not the result of any disagreement between the Company and the respective director on any matter relating to the Company's operations, policies or practices.
- (e) The Fifth Amended and Restated 2016 Share Option and Incentive Plan On June 11, 2026, at the Annual Meeting, the shareholders of the Company approved the Company's Fifth Amended and Restated 2016 Share Option and Incentive Plan (the "Amended 2016 Plan") to increase the number of authorized shares available for issuance thereunder by 75,400,000 ordinary shares.
- The Company's officers and directors are among the persons eligible to receive awards under the Amended 2016 Plan.
- Additional information about the Amended 2016 Plan is included in the Proxy Statement.
Tools for this story
Each opens in a new tab, filled in for BeOne Medicines Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.